Core outcome sets in cancer clinical trials: current status and future opportunities—an EORTC perspective
While COS are becoming increasingly available to, and acknowledged by, cancer clinical trialists, their implementation is currently still limited. Our findings indicate that further development of COS to fill gaps for missing tumour types, greater involvement of trialists in the COS development process, and increased awareness and understanding of COS amongst trialists are all required to ensure widespread implementation of COS in cancer clinical trials.
Authors
- Mieke Van Hemelrijck (ORCID: https://orcid.org/0000-0002-7317-0858)
- Ailbhe Lawlor (ORCID: https://orcid.org/0009-0008-5304-6957)
- Paula Ruth Williamson (ORCID: https://orcid.org/0000-0001-9802-6636)
- Jan Bogaerts (ORCID: https://orcid.org/0000-0003-4216-3679)
- Steven MacLennan (ORCID: https://orcid.org/0000-0002-2691-8421)
- Jens Lehmann (ORCID: https://orcid.org/0000-0002-4670-7517)
- Saskia Litière (ORCID: https://orcid.org/0000-0002-6433-4056)
- Vassilis Golfinopoulos
- Petr Szturz
Institutions
- University of Liverpool (GB)
- Universität Innsbruck (AT)
- University of Aberdeen (GB)
- London Cancer (GB)
- European Organisation for Research and Treatment of Cancer (BE)
- University Hospital Innsbruck (AT)
- University of Lausanne (CH)
Publication Details
- Journal
- Trials
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1186/s13063-025-08812-y
- Citations
- 1
- Primary Topic
- Delphi Technique in Research
- Type
- article
- Field-Weighted Citation Impact
- 4.20